紫杉醇联合FOLFOX4方案治疗晚期胃癌的临床观察

目的观察并比较紫杉醇联合FOLFOX4方案与FOLFOX4方案治疗晚期胃癌的疗效及毒副反应。方法随机将晚期胃癌患者分为两组,A组32例,采用紫杉醇联合FOLFOX4方案化疗;B组31例,采用FOLFOX4方案化疗。每2周重复,28d为1周期,每例患者至少完成2周期以上的化疗。结果A组有效率（CR＋PR）为43.7%,中位疾病进展时间5.87个月,中位生存期9.8个月;B组有效率（CR＋PR）为35.5%,中位疾病进展时间3.9个月,中位生存期8.5个月。两组有效率差异无显著性（P〉0.05）,中位疾病进展时间及中位生存期差异均有显著性（P〈0.05）。两组主要毒副反应为白细胞下降、脱发、肌肉关节痛,两组发生率比较差异具有显著性（P〈0.05）。结论紫杉醇联合FOLFOX4方案治疗晚期胃癌具有良好的疗效和耐受性。

Clinical observation of paclitaxel plus FOLFOX4 regimen for treatment of advanced gastric cancer

Objective To compare the efficacy and toxicity of paclitaxel plus FOLFOX4 regimen and FOLFOX4 regimen in the treatment of patients with advanced gastric carcinoma （AGG）. Methods A total of 63 patients with AGC were randomized into two groups. Two or more cycles of chemotherapy were completed. Group A consisted of 32 patients who received paclitaxel plus FOLFOX4 regimen and group B consisted of 31 patients who received FOLFOX4 regimen. Results The response rates （CR ＋ PR） of groups A and B were 43.7% and 35.5% , the median TTP was 5.87 and 3.9 months, and the median survival time of patients was 9. 8 and 8. 5 months, respectively. The response rates of the 2 groups had no significant difference （ P 〉 0. 05 ）. The median TFP and the median survival time had significant difference （ P 〈 0. 05 ）. The major side effect of the two groups had significant difference （P 〈 0.05 ）. Conclusion Paclitaxel plus FOLFOX4 regimen is an effective, acceptable and safe method for treatment of patients with advanced gastric cancer.